3.48
-0.04(-1.14%)
Currency In USD
| Previous Close | 3.52 |
| Open | 3.49 |
| Day High | 3.56 |
| Day Low | 3.45 |
| 52-Week High | 4.18 |
| 52-Week Low | 0.69 |
| Volume | 2.44M |
| Average Volume | 5.54M |
| Market Cap | 687.41M |
| PE | -6.44 |
| EPS | -0.54 |
| Moving Average 50 Days | 3.59 |
| Moving Average 200 Days | 2.37 |
| Change | -0.04 |
If you invested $1000 in Esperion Therapeutics, Inc. (ESPR) 10 years ago, it would be worth $205.55 as of February 21, 2026 at a share price of $3.48. Whereas If you bought $1000 worth of Esperion Therapeutics, Inc. (ESPR) shares 5 years ago, it would be worth $121.68 as of February 21, 2026 at a share price of $3.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Esperion to Participate in The 2026 Citizens Life Sciences Conference
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be a
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
GlobeNewswire Inc.
Feb 17, 2026 1:00 PM GMT
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion agai
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 11, 2026 11:00 PM GMT
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~5